How I treat advanced Hodgkin lymphoma - a global view.
作者信息
Hokland Peter, Shah Mansi, David Kevin, Evens Andrew, Auer Rebecca, Ledieu Rifca, Kreissl Stefanie, Bröckelmann Paul J, Borchmann Peter, Korula Anu, Mathews Vikram, Owattanapanich Weerapat, Trotman Judith
机构信息
Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
出版信息
Br J Haematol. 2020 Sep;190(6):837-850. doi: 10.1111/bjh.16587. Epub 2020 Jun 19.
Abstract
摘要
相似文献
1
How I treat advanced Hodgkin lymphoma - a global view.
Br J Haematol. 2020 Sep;190(6):837-850. doi: 10.1111/bjh.16587. Epub 2020 Jun 19.
2
[Therapy of Hodgkin lymphoma: chances of remission are good, treatment tolerance needs improvement].
MMW Fortschr Med. 2011 Oct 13;153(41):17. doi: 10.1007/BF03368883.
3
Report of satellite workshop on interim-PET in Hodgkin lymphoma: 8th International Symposium on Hodgkin Lymphoma, Cologne, 23 October 2010.
Leuk Lymphoma. 2011 Apr;52(4):583-6. doi: 10.3109/10428194.2010.551162.
4
Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: a randomized study caveat.
Leuk Lymphoma. 2007 Sep;48(9):1667-9. doi: 10.1080/10428190701606875.
5
Persistent positron emission tomography positivity secondary to benign histiocytic proliferation after treatment of Hodgkin lymphoma.
Leuk Lymphoma. 2007 Mar;48(3):616-8. doi: 10.1080/10428190601140058.
6
[18F]fluorodeoxyglucose positron emission tomography in the management of lymphomas.
Clin Lymphoma Myeloma. 2008 Oct;8(5):273-6. doi: 10.3816/CLM.2008.n.037.
7
[FDG-PET in Hodgkin lymphoma].
Nuklearmedizin. 2008;47(6):235-8; quiz N75-6. doi: 10.3413/nukmed-0216.
8
Combination chemoradiotherapy in early Hodgkin lymphoma.
Hematol Oncol Clin North Am. 2014 Feb;28(1):33-47. doi: 10.1016/j.hoc.2013.10.010.
9
PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study.
Ann Oncol. 2021 Jun;32(6):807-810. doi: 10.1016/j.annonc.2021.02.018. Epub 2021 Mar 3.
10
Cervical thymic hyperplasia after chemotherapy in an adult patient with Hodgkin lymphoma: a potential cause of false-positivity on [18F]FDG PET/CT scanning.
Br J Haematol. 2008 Mar;140(5):477. doi: 10.1111/j.1365-2141.2007.06901.x. Epub 2007 Dec 10.
引用本文的文献
1
[Clinical characteristics and survival analysis of pediatric Hodgkin lymphoma: a multicenter study].
Zhongguo Dang Dai Er Ke Za Zhi. 2025 Jun 15;27(6):668-674. doi: 10.7499/j.issn.1008-8830.2412144.
2
Harnessing multi-source data for individualized care in Hodgkin Lymphoma.
Blood Rev. 2024 May;65:101170. doi: 10.1016/j.blre.2024.101170. Epub 2024 Jan 14.
3
Continuum of Care for Hodgkin Lymphoma: Impact of Modern Therapy on Postacute Morbidity and Mortality.
J Clin Oncol. 2020 Dec 10;38(35):4131-4134. doi: 10.1200/JCO.20.02668. Epub 2020 Oct 8.
本文引用的文献
1
Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study.
Lancet Haematol. 2020 Feb;7(2):e146-e156. doi: 10.1016/S2352-3026(19)30218-2. Epub 2020 Jan 13.
2
Impact of imaging modality on clinical outcome in Hodgkin lymphoma in a resource constraint setting.
Br J Haematol. 2020 Mar;188(6):930-934. doi: 10.1111/bjh.16289. Epub 2019 Dec 7.
3
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma.
Blood. 2019 Oct 10;134(15):1238-1246. doi: 10.1182/blood.2019000719.
4
Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease.
Hematol Oncol. 2019 Jun;37 Suppl 1:87-91. doi: 10.1002/hon.2589.
5
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.
Lancet Oncol. 2019 Feb;20(2):202-215. doi: 10.1016/S1470-2045(18)30784-8. Epub 2019 Jan 15.
6
Survivors' perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group.
Leuk Lymphoma. 2019 Jun;60(6):1389-1398. doi: 10.1080/10428194.2018.1540781. Epub 2018 Dec 3.
7
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.
Blood. 2018 Dec 20;132(25):2639-2642. doi: 10.1182/blood-2018-07-861641. Epub 2018 Sep 28.
8
Treatment-Resistant Hodgkin Lymphoma: Defining the Role of Autologous Transplantation.
Cancer J. 2018 Sep/Oct;24(5):244-248. doi: 10.1097/PPO.0000000000000330.
9
Transplant strategies in relapsed/refractory Hodgkin lymphoma.
Blood. 2018 Apr 12;131(15):1689-1697. doi: 10.1182/blood-2017-09-772673. Epub 2018 Mar 2.
10
Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.
J Clin Oncol. 2018 Feb 10;36(5):454-462. doi: 10.1200/JCO.2017.75.2543. Epub 2018 Jan 23.
Zotero 插件